Ulipristal acetate was granted marketing authorization by the European Medicines Agency (EMA) in March 2009.
Ulipristal-acetat je dobio odobrenje za puštanje u promet od Evropske agencije za lekove (European Medicines Agency - EMA) u martu 2009. godine.